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ABSTRACT 
Autoimmunity of the central nervous system (CNS) such as in Multiple Sclerosis (MS) or its 
animal model Experimental Autoimmune Encephalomyelitis (EAE) requires the activation of 
self-reactive immune cells and the presentation of self-antigen by mature antigen 
presenting cells (APCs). 
In this thesis I have studied genetic and environmental mechanisms affecting APCs and 
CD4+ T cells which regulate susceptibility to EAE induced with myelin oligodendrocyte 
glycoprotein (MOG) in the rat. 
Bone marrow derived dendritic cells (BMDCs) are frequently used as in vitro alternatives to 
APCs, particularly DCs observed in vivo. However it is crucial to discriminate which cell type 
is being generated as they will serve different functions. In paper I, we have first 
phenotypically and functionally characterized different types of in vitro generated BMDCs 
with different protocols. We have shown that BMDCs generated with FMS-like tyrosine 
kinase 3 ligand (FL-BMDCs) shared gene expression and characteristics of classical DCs 
observed in the body. We also demonstrated that BMDCs generated with the cytokines GM-
CSF and IL-4 (G4-BMDCs) were pro-inflammatory and resembled monocytes derived DCs 
(MCs) generated in vivo under inflammatory conditions. 
In the EAE model, APCs are crucial for the priming of CD4+ T cells in the draining lymph 
nodes following immunization, as well as their reactivation in the CNS prior to disease onset. 
In paper II, we have characterized how two c-type lectin receptors (CLRs), MCL and Mincle, 
conferred susceptibility to EAE by directing the re-activation of CD4+ T cells in the CNS 
towards the pathogenic IL-17-producing T helper (Th17) phenotype. We showed that this 
was in part due to the alarmin SAP130, an endogenous ligand of MCL and Mincle. 
Furthermore, we determined that the MCL/MINCLE signaling pathway was hyperactive in 
MS blood monocytes and might contribute to disease severity. 
Many environmental factors have been linked to increased risk of developing MS including 
lack of sun exposure and vitamin D deficiency. In paper III, we described how vitamin D 
affects the activation of CD4+ T cells via epigenetic mechanisms (miRNA, DNA methylation 
and histone modification) resulting in a reduction of their pathogenic potential. 
This thesis showed, using different approaches in rodent models and human material, how 
genetic and environmental factors relevant for MS could regulate susceptibility to EAE by 
modulating the development of pathogenic Th17 cells. In paper I, we characterized BMDCs 
routinely used in vitro to study immune functions of myeloid cells. In paper II and paper III, 
we addressed two distinct mechanisms regulating T cell activation and EAE development. 
This work presented integrative strategies to address biological questions and provided 
novel insight into the immunological aspects of autoimmune neuroinflammation. 
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1. Introduction 
Research on basic immunology, Multiple Sclerosis (MS) and its animal model Experimental 
Autoimmune Encephalomyelitis (EAE) is very active and knowledge continues to expand every 
day, leading to an extensive amount of information. The goal of this section is to provide the 
reader with sufficient background knowledge in order to understand the work done in this 
thesis.  
I. The immune system 
The role of the immune system is to protect us from disease, such as infection and cancer. Our 
body contains a tightly regulated network of cells whose sole purpose is to defend us against 
extrinsic attacks and intrinsic hazards (Fig. 1).  
 
Fig. 1 Human body showing the various organs of the immune system and the distribution of the various immune cells into 
the immune organs and other organs that are rich in macrophages. Mahmoud Elsabahy and Karen L. Wooley, “Cytokines as 
biomarkers of nanoparticle immunotoxicity”, Chemical Society Reviews  2013;42:5552-55761 
A normal immune response has an inflammatory phase (to remove the threat) followed by 
the resolution of the inflammation and an anti-inflammatory phase (to enable tissue repair 
and return of physiological functions). The regulation of an immune response occurs in space 
and time to prevent damage to adjacent non-affected tissue or prolonged damage to the 
affected organ (as occurring during chronic inflammation). 
However, dysregulation of the immune system can cause disease itself, such as allergy or 
autoimmunity. Allergy is a hypersensitivity reaction of the immune system to antigens that do 
not generate immune responses in most people (e.g. food or pollen allergies, asthma). 
Autoimmunity is an aberrant response of the immune system to self-antigen, resulting in 
organ dysfunction and possibly death (e.g. type 1 diabetes, rheumatoid arthritis, multiple 
sclerosis).  
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The components of the immune system can be separated into two parts: the innate and the 
adaptive immune systems.  Both parts are complementary arms of inflammation and can 
contribute to different phases of the immune response (initiation, propagation and 
resolution). 
a) Cytokine network 
Cytokines are soluble signaling molecules that regulate many bodily functions during 
homeostasis through promoting communication between immune and non-immune cells2. 
During inflammation, activation of innate immune cells induces the production of a specific 
cytokine signature that will dictate the subsequent adaptive immune response. Cytokines 
influence the expression of other cytokines and can cause, if not tightly regulated, a cytokine 
storm or cytokine cascade that can be potentially fatal for the host, as evident in cases of 
sepsis.  
b) The innate immune system 
The innate immune system developed earlier during evolution than the adaptive immune 
system and includes cells capable of sensing infection and tissue damage 3-5. These cells are 
also crucial in shaping the subsequent adaptive immune response. The innate immune system 
comprises natural killer cells, innate lymphoid cells, mucosal associated invariant T cells, 
basophils, eosinophils, mast cells as well as phagocytic cells such as dendritic cells (DCs), 
macrophages, monocytes and neutrophils. The work of this thesis mainly focuses on the role 
of phagocytic innate immune cells and they will be described further in the next section.  
(i) Peripheral innate immune system: dendritic cells, neutrophils, tissue 
monocytes and macrophages 
 
 
Fig. 2 Macrophages and dendritic cells ontogeny. Myron I. Cybulsky, Cheolho Cheong and Clinton S. Robbins, “Macrophages 
and Dendritic Cells Partners in Atherogenesis”, Circulation Research. 2016;118:637-6526 
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The passage of fluids between the blood, tissue and lymph allows the circulation of nutrients 
to the tissue and the drainage of waste and microorganisms. Blood, interstitial fluid and lymph 
can collect and transport pathogens to the lymphoid organs, i.e. lymph nodes and spleen, 
where antigen presenting cells (APCs) can capture and present antigens to lymphocytes. 
Moreover, APCs are also present in abundance in barrier tissues such as the skin and mucosa 
(gut, nose, lungs) where they can form discrete structures of lymphoid tissue named skin, 
mucosal or nasal -associated lymphoid organs (SALT, MALT, NALT respectively) or migrate to 
the lymphoid organs. Thereafter, APCs can interact with lymphocytes and shape an 
appropriate immune response to pathogens or respond to damage.  
Dendritic cells are the most potent of all the APCs and constitutively express the surface 
protein major histocompatibility complex (MHC) class II7. Their name arises from their star 
shape, with lots of protruding extensions or dendrites that enable them to sample the 
environment for dangers such as pathogens or damaged cells. While the existence of DCs is 
well accepted since their discovery by Ralph Steiman in 19738 (for which he was awarded a 
Nobel prize in 2011), distinguishing DCs from other phagocytic cells has always been a 
challenge as many markers that were thought to be DC-specific (e.g. CD11c) proved to be 
expressed by other immune cells in both health and disease states. A new nomenclature based 
on ontogeny allowed for the distinction of true DCs from monocyte-derived dendritic-looking 
cells9. DCs arise from bone marrow hematopoietic stem cells from a distinct common dendritic 
precursor, and can be divided into two subclasses: plasmacytoid DCs (pDCs) and classical DCs 
(cDCs) 10-13 (Fig. 2). pDCs are present in the blood as well as in lymphoid organs and their 
morphology is more similar to that of plasma cells. They are a major source of type I interferon 
(IFN) and are crucial for antiviral responses14-16. They can also greatly contribute to 
autoimmune disease with strong type I IFN signatures such as in systemic lupus erythematous 
(SLE)17. Pre-cDCs exit the bone marrow and populate the tissue and secondary lymphoid 
organs where they differentiate into immature cDCs10,11. Once activated by danger signals, 
mature tissue DCs upregulate CCR7 and migrate to the draining lymph nodes where they 
activate cells of the adaptive immune system18,19. DCs residing in the spleen and lymph nodes 
can survey for danger signals present in body fluids (blood, lymph)20. 
Neutrophils are short-lived phagocytes that egress from the bone marrow fully mature and 
circulate in the blood21. They are one of the first immune cells recruited by local APCs to the 
sites of infection or damage. They are potent effector cells that can cause great tissue damage 
if not tightly regulated. Indeed, once activated they can release cytokines22,23, proteases24 and 
reactive oxygen species25 or generate extracellular traps26,27 (netosis) in order to destroy the 
invading pathogens and to propagate inflammation. Apoptotic dying neutrophils facilitate the 
resolution of inflammation by preventing the further recruitment of neutrophils and 
promoting their clearance by macrophages28,29.  
Monocytes are generated in the bone marrow and migrate to the blood (Fig. 2). They can be 
separated into two main subsets, classical and non-classical monocytes, in human (CD14+ and 
CD14low CD16+), mouse (LY6Chi CCR2+ CD62L+ CX3CR1mid and LY6Clow CD43+ CX3CR1hi) and rats 
(CCR2hi CX3CR1low CD43low and CCR2low CX3CR1hi CD43hi)30,31. Monocytes do not contribute to 
the majority of tissue macrophage pools except in some specific areas such as the gut, skin, 
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pancreas, heart, choroid plexus and possibly liver32,33. However, they are rapidly recruited to 
inflammatory sites where they can differentiate into macrophages or dendritic-like cells and 
contribute to inflammation34 (Fig. 3). Non-classical monocytes patrol the blood vessels and 
are important for vascular repair, and are also thought to play a role in the resolution of 
inflammation by promoting wound healing35,36 (Fig. 3).  
 
Fig. 3 The mouse monocyte compartment. Florent Ginhoux and Steffen Jung, “Monocytes and macrophages: 
developmental pathways and tissue homeostasis”, Nature review Immunology 2014;14:392–40437 
Macrophages are present throughout the whole body, colonizing the different tissues during 
embryonic development and early life (Fig. 2)38-44. The organ environment will affect resident 
macrophages in adopting certain shapes and functions that are necessary for tissue 
maintenance and homeostasis (Fig. 4). For instance, osteoclasts play a crucial role in bone 
remodeling45 and alveolar macrophages are necessary for pulmonary surfactant catabolism46. 
Once seeded throughout the body most macrophage subsets are able to self-renew and 
maintain their numbers during homeostasis with little or no contribution from blood 
monocytes33,47.  
In response to threats, local APCs (macrophages or DCs) as well as patrolling non-classical 
monocytes will be activated and recruit neutrophils to the site of insult by secreting 
chemokines (CXCL1, CXCL2). The inflammatory environment will activate the neutrophils and 
lead to the recruitment of more immune cells such as classical inflammatory monocytes. Time 
or the clearance of danger will lead to the death of neutrophils and other infiltrating immune 
cells by apoptosis, which will in turn facilitate the resolution of inflammation and tissue 
repair48 (Fig. 5).  
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Fig. 4 Tissue macrophages perform important homeostatic functions. Peter J. Murray and Thomas A. Wynn, “Protective and 
Pathogenic Functions of Macrophage Subsets”, Nature review immunology, 2001;11:723–73749 
 
 
Fig. 5 Phagocyte interactions in inflammation. Oliver Soehnlein and Lennart Lindbom, “Phagocyte partnership during the 
onset and resolution of inflammation”, Nature reviews Immunology 2010;10:427–43948 
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(ii) Microglia and Meningeal/Perivascular/Choroid plexus Macrophages 
Microglia are the resident macrophages of the central nervous system (CNS) parenchyma (Fig. 
6). Like other macrophages, they are the first myeloid cells seeded in the CNS during 
embryogenesis and can self-renew in situ without contribution from blood monocytes41. They 
are important for CNS development, helping to shape the neuronal circuit50,51. During post-
natal life they monitor the environment for danger and support neuronal functions52,53. 
Resting microglia have a highly ramified shape with long processes which allow them to 
monitor their surroundings. Once activated, they assume an amoeboid shape and can 
promote inflammation which, if not controlled, can contribute to tissue damage. 
 
Fig. 6 Myeloid cell types in the CNS. Marco Prinz and Josef Priller, “Microglia and brain macrophages in the molecular age: 
from origin to neuropsychiatric disease”, Nature review neuroscience, 2014; 15:300–31254 
Non-parenchymal macrophages are present within the meninges, around the blood vessels 
and in the choroid plexus 55(Fig. 6). These macrophages are strategically placed between the 
cerebrospinal fluid (CSF) and blood vessels or at the interface of the interstitial fluid and blood 
in order to monitor and respond to events within the CNS while also responding to peripheral 
influences55. Similar to other macrophages, they can also express MHC class II (MHC-II) once 
activated and are therefore capable of presenting antigens to T cells56. 
c) The adaptive immune system 
While the innate immune system provides a first line of defense against threats, the activation 
of the adaptive immune system is crucial to provide highly specific and long-lasting 
immunological memory.  
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(i) The T lymphocytes 
T cells are lymphocytes that develop in the bone marrow but mature in the thymus. They can 
be separated into three functional subsets, (a) helper T cells, (b) cytotoxic T cells and (c) 
regulatory T cells. As this thesis mainly focuses on the role of T helper (Th) cells, I will briefly 
introduce the two other subsets before focusing on Th cells. 
Cytotoxic T cells mainly express the CD8 marker, although there have been recent reports of 
CD4+ cytotoxic lymphocytes. Their role is to directly kill cells that they recognize via the MHC 
class I (MHC-I) for CD8+ cells or MHC-II for CD4+ cells57. This is the case for virally infected cells 
or tumor cells, for example. On the contrary, regulatory T cells (Tregs) are mostly known as 
CD4+ Tregs but can also be CD8+ cells. There are 2 main subsets of Tregs, those that arise 
directly from thymic selection named thymic Tregs (tTregs), and those that arise from 
peripheral activation named induced pTregs. In vitro induced Tregs are referred to as iTregs. 
Regulatory T cells are important to regulate immune responses as they exert 
immunosuppressive actions through different mechanisms58.  
 
Fig. 7 Simplified scheme of T cell differentiation pathways and plasticity (dashed arrows). Ekaterina A. Ivanova and 
Alexander N. Orekhov, “T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview”, BioMed 
Research International, 201559 
T helper lymphocytes, mainly CD4+ cells, are at the heart of the adaptive immune response. 
They are crucial for relaying the information provided by the activated APCs in order to 
produce an appropriate adaptive response to danger60. Absence of T helper cells represents a 
major limitation in our defense against pathogens, as evident in HIV patients affected by 
AIDS61. In a nutshell, three steps are necessary for the activation of CD4+ T cells. Signal 1: 
mature APCs present antigen in the context of MHC-II that will be recognized by the T cell 
receptor (TCR). Signal 2: mature APCs upregulate co-stimulatory molecules (e.g. CD80, CD86) 
that can be recognized by receptors on the T cells (e.g. CD28). Signal 3: mature APCs secrete 
a pattern of cytokines specific for the danger encountered that will determine the type of Th 
cell the activated T cell will become62,63 (Fig. 7).  
Th1 and Th17 lymphocytes are two pro-inflammatory subsets of Th cells. Th1 cells are 
important for the response to intracellular bacteria such as Mycobacteria tuberculosis, while 
Th17 cells are crucial for anti-fungal immunity (e.g. Candida albicans). Th1 cells are induced 
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by the cytokines IL-12 and IFNγ via the transcription factor Tbet and can produce tumor 
necrosis factor (TNF) and IFNγ that will boost macrophage activation and reactive oxygen 
species production64,65. Th17 cells are induced by IL-1, IL-6 and TGFβ via the transcription 
factor Rorγt66,67. They produce the cytokines IL-17, IL-21 and IL-22 that will boost the 
activation of immune and non-immune cells as well as neutrophil recruitment68,69. Both 
subsets have been implicated in autoimmunity and since most of the knowledge about their 
role arises from animal studies they will be discussed in more detail in section III. 
(ii) The B Lymphocytes 
B cells are the effectors of the humoral branch of adaptive immunity. Their main role is to 
provide long-term protection against pathogens by secreting specific antibodies. B cells are 
also very good antigen presenting cells and producers of cytokines. The work of this thesis 
focuses on the interaction of T cells with APCs, but B lymphocytes seem to also be key players 
in multiple sclerosis pathogenesis70.  
d) CNS immunity 
 
Fig. 8 The CNS immune system during homeostasis. Prinz M and Priller J, “The role of peripheral immune cells in the CNS in 
steady state and disease”, Nature review Neuroscience 2017;20:136–14471 
For a long time the CNS was considered to be ‘immune privileged’ due to its inability to reject 
grafts and because it is protected from immune invasion by a semi-permeable multi-layered 
barrier that limits the entry of cells and molecules from the blood, namely the blood-brain or 
blood-CSF barrier (BBB and BCB, respectively). However, macrophages and dendritic cells, as 
well as other innate immune cells, populate different areas of the CNS, including the 
meninges, in steady-state, and memory/activated T cells patrol the CNS during homeostasis71-
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73. Furthermore, the CNS is capable of sensing and responding to peripheral inflammation, 
resulting in resident cell activation and cytokine production74. Finally, CNS antigens can be 
found in deep cervical lymph nodes either traveling via the dural or nasal lymphatics75-78. 
Therefore, all the elements are in place to enable both innate and adaptive immune responses 
within the CNS (Fig. 8).   
e) PAMPs, DAMPs and PRRs 
Invading pathogens can be recognized by the immune system through conserved motifs 
named pattern-associated molecular patterns (PAMPs). Cells of the immune system, mostly 
innate immune cells, express receptors named pattern recognition receptors (PRRs) capable 
of recognizing such motifs. In an ideal scenario, recognition of PAMPs by PRRs results in cell 
activation and induces an inflammatory response specific for the type of pathogen recognized, 
which is ultimately eliminated. PRRs can also recognize endogenous molecules that are 
released by activated, stressed or damaged cells called danger/damage associated molecular 
patterns (DAMPs). These molecules are capable of inducing an inflammatory response in the 
absence of infectious pathogens, a process referred to as sterile inflammation79,80. 
There are many types of PRRs including toll-like receptors (TLRs), retinoic acid-inducible gene 
I -like receptors, nucleotide-binding leucine-rich repeat containing receptors and C-type lectin 
receptors (CLRs). While the most studied family of PRRs is probably the TLRs, the focus of this 
thesis is on CLRs. This large superfamily contains over a thousand members and, despite 
having been discovered over 100 years ago, only recently has there been an increased interest 
in their investigation81. We have been particularly interested in two CLRs of the Dectin-2 
cluster, macrophage C-type lectin (MCL, Clec4d) and macrophage inducible C-type lectin 
(Mincle, clec4e), which can be found on human chromosome 12, mouse chromosome 6 and 
rat chromosome 482,83 (Fig. 9). 
 
Fig. 9 The Dectin-2 cluster of C-type lectins. Adapted from Kerscher82 B, Willment JA and Brown GD, “The Dectin-2 family of 
C-type lectin-like receptors: An update”, International Immunology 2013;25(5):271-277. 
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Members of the Dectin-2 cluster also include BDCA-2, DCAR, Dectin2 and DCIR. These 
receptors are primarily expressed by antigen presenting cells of myeloid origin. Different PRRs 
induce different signaling cascades and gene inductions; Figure 10 shows a schematic 
comparing signaling of CLRs to TLRs84.  
 
Fig. 10 Schematic comparison of CLR and TLR signaling. Jenny Ostrop and Roland Lang, “Collaboration, and Conflict: Signal 
Integration of Syk-Coupled C-Type Lectin Receptors”, Journal of Immunology 2017;198(4):1403-141484 
Members of the Dectin-2 cluster are activating receptors which signal via FCRγ, Syk, and 
CARD9-BCL10-MALT1 to induce NF-κB activation (Fig. 11). Moreover, the syk-CARD9 pathway 
of CLR signaling induces the production of IL-1β, IL-6 and IL-23 by immune cells that can in 
turn promote the differentiation of T cells to the Th17 phenotype85-89. 
 
Fig. 11 Signaling through Mincle and MCL. Mark B. Richardson and Spencer J. Williams, “MCL and Mincle: C-type lectin 
receptors that sense damaged self and pathogen-associated molecular patterns”, Frontiers in immunology 2014;5:28890 
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MCL and Mincle recognize a plethora of ligands from fungus to bacteria or endogenous 
proteins, as summarized in table 1.  
Table 1:  Overview of microbial and endogenous ligands of Mcl and Mincle 
Ligand Comments References 
Mcl (Clec4d) 
Klebsiella pneumoniae Protective role in infection model 91 
Mycobacterium tuberculosis, Mycobacterium bovis Protective role in infection model 92 
TDM from Mycobacterium spp. Mouse, human, not guinea pig 93-96 
Blastomyces dermatitidis Mouse 97 
Candida albicans Controversial role in infection models 98,99 
Cryptococcus neoformans Protective role in infection model 100 
Mincle (Clec4e) 
Cholesterol crystals (endogenous) CRAC motif, human, not mouse/rat 101 
SAP130, dead cells (endogenous) Ca2+-independent, VEGQ motif 102-107 
Cholesterol sulfate (endogenous) Mouse 108 
B-glucosylceramid (endogenous) Mouse 109 
Helicobacter pylori Human 110 
K. pneumoniae Protective role in infection model 111 
Streptococcus pneumoniae Mouse 112 
M. tuberculosis, M. bovis, Mycobacterium smegmatis Controversial role in infection models 113-117 
Cyclopropane–fatty acid α-glucosyl diglyceride 
from Lactobacillus plantarum Mouse/human 
118 
β-Gentiobiosyl diaglycerides from M. 
tuberculosis (H37Ra) Mouse, not human 
119 
TDM from Mycobacterium spp. Ca2+-dependent, mouse/human/guinea pig/cow 
93-95,113,114,120-123 
Synthetic trehalose diesters, including TDB, 
corynomycolates Mouse/human 
93,95,113,120,121,124-128 
Synthetic trehalose monoesters Mouse 129 
Glycerol monomycolate (MMG, GroMM) Human, not mouse 130 
Brartemicin Mimicks glycolipid binding 131 
C. albicans Mouse/human 122,132,133 
Cladophialophora carrionii Human 134 
Fonsecaea pedrosoi, Fonsecaea monophora, 
Fonsecaea compacta Mouse/human 
134-136 
Malassezia furfur, glycolipid Mouse 126,137 
Adapted from Jenny Ostrop and Roland Lang, “Collaboration, and Conflict: Signal Integration of Syk-Coupled C-Type Lectin 
Receptors”, Journal of Immunology 2017;198(4):1403-141484 
Mincle has been more extensively studied than MCL and it is still unclear how those two 
receptors relate to each other. It has been postulated that MCL cannot interact directly with 
FcRγ due to a missing arginine residue in the stalk region138,139. While some groups report that 
MCL signals by forming a heterodimer with Mincle140, others have found that it can bind to 
FcRγ in the absence of Mincle using a serine residue at position 38141,142 (Fig. 11).  
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Moreover, the mechanisms mediating receptor surface expression are still unclear. While 
some studies report that MCL ligand binding induces Mincle expression141, others show that 
the receptors stabilize each other’s surface expression by forming heterodimers140,143-145. 
f) In vitro, in vivo and ex vivo methods to study the immune system 
 
(i) Forward genetic and congenic strains 
The rat model was the leading choice in research until the development of transgenic mice 
over 25 years ago. Even though the current strategies for transgenic rats are still very limited, 
research still benefits in using rat models due to the closer physiology between rats and 
humans, as compared to mice and humans. Moreover, rats are easier to handle, with a larger 
size allowing optimal surgery and sampling conditions which make working with rats attractive 
despite the challenges in the reduced number of commercial reagents. The rat genome was 
published in 2004146 and our laboratory sequenced the genome of our in-house Dark Agouti 
(DA) and Piebold-Viral-Glaxo (PVG) strains. This knowledge, along with defined breeding 
strategies such as F2 crosses and advanced intercross lines (AILs), allowed us to study genetic 
susceptibility and resistance to neuroinflammation. By backcrossing the offspring of DA and 
PVG rats to one of the parental strains for more than 5 generations, we were able to generate 
congenic strains and assessed their phenotypes in response to inflammation. This gave us the 
tools for a forward genetic approach in order to identify genes responsible for the observed 
phenotype (as in paper II). 
(ii) Cell culture and in vitro stimulation 
As mentioned before, one of the advantages of the rat models is the larger organ size. This 
allows for the primary culture of many different types of cells from harvested organs, in a 
sufficient amount to test several experimental conditions. Undoubtedly, a major drawback is 
that by lacking the complexity of an integrated system such as the body and tissue, 
mechanisms investigated using cells obtained in vitro do not closely mirror the original 
processes in vivo. Moreover, the artificial manipulation in vitro might generate a cell type that 
does not exactly reflect cells seen in vivo. In paper I, we investigate the difference between in 
vitro generated bone marrow-derived DCs with the aim to make a parallel with their possible 
in vivo counterparts. 
(iii) T cell culture and differentiation assay 
One can generate T cell lines that are specific for a particular antigen from a pool of T cells of 
different specificity. After immunizing the rats against the specific antigen subcutaneously, 
the draining lymph nodes will contain a plethora of activated T cells, some being specific for 
the antigen of interest. Using rounds of in vitro stimulation and amplification one can enrich 
for antigen-specific T cells. These cells can be manipulated during this phase and then be used 
for in vivo or in vitro assays. In paper III we used adoptive transfer of myelin basic protein 
(MBP) specific T cells to assess the effect of vitamin D on CD4+ T cell pathogenicity. 
As previously mentioned, naïve Th cells can become activated into different subsets. The 
cytokine signature of the cells helps determining their subset specificity (Th1 or Th17). The 
expression of the transcription factor FoxP3 determines if the cells are regulatory (Tregs). 
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Resting CD4+ T cells, selected for their lack of the marker CD25, can be artificially activated in 
vitro using anti-CD3 (signal 1) and anti-CD28 (signal 2) antibodies. We used this knowledge to 
test the effect of signal 3 on determining T cell fate in paper I and paper II. 
(iv) Flow cytometry 
Flow cytometry is one of the greatest tools in immunological research. It is a laser-based 
technique that enables determination of the level of expression of surface or intracellular 
markers by cells in suspension, thanks to their interaction with specific fluorescently-labelled 
antibodies. Moreover, the flow cytometer can discriminate cells according to their size and 
granularity. This was the technique most used in this thesis in order to assess activation of 
different subsets of immune cells, or to determine the level of cytokines produced by T cells 
ex vivo or in vitro (paper I, II and III). We also used flow cytometry to assess the phagocytosis 
of fluorescently-labelled beads and pathogens (paper I). 
(v) Bone marrow chimeras 
In order to separately study the effect of hematopoietic cells from the cells of the rest of the 
body one can use bone marrow chimeric animals. Similar to the mouse model, the rat model 
relies on the ablation of the hosts’ hematopoietic stem cells using lethal irradiation and their 
replacement with new hematopoietic cells from freshly isolated donor bone marrow. 
Unexpectedly, in the rat model, we also observed the replacement of meningeal and 
perivascular macrophages by cells derived from the donor bone marrow, impeding in this case 
the assessment of the effect of those cells alone in paper II.  
(vi) siRNA knock-down and blocking antibodies 
As technology for transgenic animal is limited in rats, we used the small interfering RNA 
(siRNA) technology that enables the transient suppression of messenger RNA (mRNA). siRNA 
target the complementary mRNA for degradation via the RNA-Induced Silencing Complex 
(RISC). This leads to no translation and a reduction of protein expression. We have successfully 
used siRNA targeting MCL and Mincle in vitro and in vivo in paper II. 
(vii) qPCR and ELISA 
Quantitative polymerase chain reaction (qPCR) allows for the quantification of gene transcript 
expression in tissues or cells. Level of expression is calculated related to stably expressed 
housekeeping genes (e.g. Actin). The method relies on the quantification of the transcripts, 
amplified using sequence-specific primers and detected using a fluorescent dye (i.e. Sybr 
Green) that intercalates itself with the newly generated double-stranded DNA.  
Enzyme-linked immunosorbent assay (ELISA) is an antibody-based technique that allows for 
the detection of proteins in fluids (serum, CSF, cell media). This method was used to quantify 
cytokine production by activated bone marrow derived dendritic cells (BMDCs) in paper I. 
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II. Multiple Sclerosis 
a) Clinical manifestation 
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system affecting mainly young adults in their late twenties or early thirties. Symptoms for MS 
are very varied as they depend on the spatial localization of the MS plaque (Fig. 12). MS lesions 
form areas of focal demyelination and immune infiltration. Neuronal damage also occurs in 
MS ultimately resulting in a loss of brain volume over time. 
 
Fig. 12 Symptoms of MS. 
MS plaques can be visualized using magnetic resonance imaging (MRI) and their presence is 
part of the diagnostic criteria for MS147,148. There is no straightforward diagnosis for MS as 
clinicians are still lacking unambiguous test that can alone confirm MS disease specifically. 
Physicians rely on the inclusion of different diagnostic criteria and the exclusion of other 
diseases (using blood tests, MRI and CSF analysis) to conclude if a patient is afflicted with MS 
or not. Most patients accumulate disabilities over time and experience a drastic reduction in 
their quality of life. It is interesting to note that not all MS lesions will give physical symptoms, 
suggesting that by the time a patient receives an MS diagnosis they might have already been 
afflicted by the disease for several years albeit under a sub-clinical threshold149-151 (Fig. 13). 
Clinically isolated syndrome (CIS) could be considered the first clinical form of MS 
manifestation. It is a first occurrence of neurological symptoms due to inflammation or 
demyelination in the CNS. CIS patients with MRI lesions have a high risk of converting to MS152. 
The majority of MS patients experience a relapsing remitting pattern in their disease course 
(RRMS), with bouts of inflammatory attacks followed by periods of remission during which full 
or partial recovery can occur. Most RRMS patients will enter a second progressive phase of 
the disease (SPMS) with a gradual increase of disabilities with or without evidence of disease 
activity by MRI. About 10% of patients present a progressive form of the disease (PPMS), 
usually at a later age of onset, with steady functional decline without remission153 (Fig. 13). 
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Fig. 13 Evolution of multiple sclerosis. Tomas Olsson, Lisa F. Barcellos and Lars Alfredsson, “Interactions between genetic, 
lifestyle and environmental risk factors for multiple sclerosis”, Nature reviews neurology 2016;13:25–36150 
b) Etiology, risk factors, biomarkers and pathogenesis 
(i) Etiology 
The cause of MS is still unknown but many genetic risk variants and environmental factors 
that can contribute to disease have been identified. It is believed that the interaction of both 
genetic and the environmental risk factors can favor the development of MS. However, 
different individuals might display different combinations of effects leading to disease. One 
can therefore question whether MS is a disease with a common pathogenesis or a syndrome 
due to different mechanisms.  
MS lesions can affect all areas of the CNS, including the brain (brainstem, juxtacortical and 
perivascular white matter, cerebellum), spinal cord (subpial white matter) and optic 
nerve154,155. Lucchinetti and colleagues have described four patterns of early active 
demyelinating MS lesions from autopsy and biopsy material156. Pattern I represents 15% of 
cases and cells in the lesion consist of macrophages and T cells; pattern II is observed in 56% 
of patients with the presence of complement and/or antibodies; pattern III is seen in 26% and 
biopsies show cellular infiltration plus oligodendrocyte death in plaque and peri-plaque; 
pattern IV is very rare and while it shows very few immune cells there is a profound 
oligodendropathy in the plaque and peri-plaque. All patterns show the presence of myeloid 
phagocytes and T cells, with phagocytes outnumbering lymphocytes. While patterns I and II 
represent plaques in which myelin is destroyed with some preservation of oligodendrocytes 
and remyelination, pattern II and IV exhibit hyper-sensibility of oligodendrocytes to the 
inflammatory response resulting in their death and reduced remyelination155. However, it 
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seems that all the active plaques within the same patients are of the same pattern157,158. While 
there is intra-patient homogeneity, the inter-patient heterogeneity supports the possibility 
that the underlying pathogenesis relies on different mechanisms. It would be interesting to 
determine whether patients presenting pattern II or IV have a more severe disease 
progression. 
(ii) Risk genes and environmental factors 
 
Fig. 14 Significant non-MHC association clusters in MS identified by GWAS-NR. J P Hussman, A H Beecham, M Schmidt, E R 
Martin, J L McCauley, J M Vance, J L Haines and M A Pericak-Vance,  “GWAS analysis implicates NF-κB-mediated induction 
of inflammatory T cells in multiple sclerosis”, Genes and immunity 2016;17(5):305–312159 
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Genome wide association studies (GWAS) have identified over 200 risk variants that can alter 
the risk for MS160. The strongest association maps to the human leukocyte antigen (HLA) class 
II region (HLA-DRB1*15:01 haplotype)161 and most of the other non-HLA risk loci include genes 
modulating the immune system162. This supports the notion that MS is an immune-mediated 
disease of the CNS rather than a primary CNS degenerative disease. MS is a complex disease 
and each identified risk locus has small effect on disease risk. Single nucleotide polymorphisms 
(SNPs) can be located in coding or non-coding regions of the genome. When they occur in 
coding areas they might change the amino acid sequence (non-synonymous) or not 
(synonymous), and impact gene expression of the affected gene. When in non-coding regions 
they might primarily affect gene expression not only of the nearest gene but also distal ones 
via diverse mechanisms (e.g. enhancer/promoter region)163. This makes understanding which 
genes are affected by a SNP not a trivial matter. Moreover, association studies rely on the 
genotyping of tag SNPs representative of haplotype blocks (segment of DNA with genes that 
are often inherited together), which, together with the extensive polymorphic nature of some 
immune-related loci, e.g. the MHC locus, muddied even more the search for the causative 
gene(s)164. 
Nonetheless, putative risk genes have been identified and several are involved in signaling by 
a broad range of adaptive and innate immune cells. Of particular interest to us are BCL10 and 
MALT1 that participate in T, B and myeloid cell responses via the NF-κB pathway including the 
response to the CLRs, MCL and Mincle159,165 (Fig. 14). 
The disease discordance between monozygotic twins166 and the increased incidence and 
prevalence of autoimmune diseases worldwide167-171 suggest that in addition to the genetic 
risk factors, many lifestyle and environmental factors can affect the risk of developing 
autoimmune states such as MS (Table 2). Some of the strongest risk comes from smoking, lack 
of sun exposure/ vitamin D deficiency, diet or infections150,172-179.  
 
Fig. 15 Vitamin D metabolism. Wendy Dankers, Edgar M. Colin, Jan Piet van Hamburg and Erik Lubberts, “Vitamin D in 
Autoimmunity: Molecular Mechanisms and Therapeutic Potential”, Frontiers in Immunology 2017;7:697 
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Table 2: Established and possible lifestyle and environmental risk factors for MS 
Factor OR HLA gene interaction 
Combined OR 
(nongenetic 
factor + HLA 
allele) 
Effect during 
adolescence 
Immune 
system 
implied 
Level of 
evidence 
Smoking ∼1.6 Yes 14 No Yes +++ 
EBV infection 
(seropositivity) ∼3.6 Yes ∼15 Yes Yes +++ 
Vitamin D level 
<50 nM ∼1.4 No NA Probably Yes +++ 
Adolescent 
obesity (BMI >27 
at age 20 years) 
∼2 Yes ∼15 Yes Yes +++ 
CMV infection 
(seropositivity) 0.7 No NA Unknown Yes ++ 
Night work ∼1.7 No NA Yes Yes ++ 
Low sun 
exposure ∼2 No NA Probably Yes ++ 
Infectious 
mononucleosis ∼2 Yes 7 Yes Yes ++ 
Passive smoking ∼1.3 Yes 6 No Yes + 
Organic solvent 
exposure ∼1.5 Unknown Unknown Unknown Unknown + 
Oral 
tobacco/nicotine 0.5 No NA Unknown Yes + 
Alcohol ∼0.6 No NA Unknown Yes + 
Coffee ∼0.7 No NA Unknown Yes + 
Level of evidence for a role of a particular lifestyle or environmental factors in MS is not easy to define. Large 
prospective studies are, with few exceptions, rare in MS. CMV, cytomegalovirus; EBV, Epstein–Barr virus; HLA, 
human leukocyte antigen; MS, multiple sclerosis; NA, not applicable; OR, odds ratio; +++, high level of evidence: 
drawn from large prospective studies or if a case–control observation is supported by Mendelian randomization 
studies; ++, Case–control observations, if replicated and/or supported by independent methods; +, Non-
replicated observations (included to enable further observations). 
Adapted from Tomas Olsson, Lisa F. Barcellos and  Lars Alfredsson, “Interactions between genetic, lifestyle and 
environmental risk factors for multiple sclerosis”, Nature reviews neurology 2016;13:25–36 
Vitamin D deficiency may play a role in many autoimmune diseases other than MS, such as 
SLE, Crohn’s disease, type I diabetes and rheumatoid arthritis180. While vitamin D 
(cholecalciferol) can be obtained via the diet, the main source is produced in the skin in 
response to UV lights (Fig. 15). 
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Fig. 16 Potential mechanisms of vitamin D immunomodulation. Martina B. Sintzel, Mark Rametta and Anthony T. Reder, 
“Vitamin D and Multiple Sclerosis: A Comprehensive Review”, Neurology and Therapy 2017:1-27181 
(iii) Pathogenesis (innate/adaptive/CNS immune system, CNS resident cells, meningeal 
inflammation) 
While most people have autoreactive T cells, not everybody develops MS. The reason for this 
could be due to two non-mutually exclusive hypotheses: the immune system of MS patients 
is more reactive, or their CNS is more sensitive to attack due to intrinsic pathologies or 
infections. The numerous risk loci affecting the immune system and the different patterns of 
lesions support both possibilities. Moreover, myelin reactive T cells of MS patient produce 
more pro-inflammatory cytokines (IFNγ, IL-17, GM-CSF) and less anti-inflammatory cytokines 
(IL-10) than those of controls182. 
The different phases of disease observed in MS patients seem to be due to different sources 
of immune cells. While the relapsing/remitting phase seems to depend on the entry of 
peripheral immune cells to the CNS, the progressive phase of the disease seems to be 
dependent on inflammatory events sequestered in the CNS with little input from peripheral 
cells183. RRMS is thought to be driven by activated self-reactive CD4+ T cells that are present 
in the CNS and promote the entry of other immune cells, as well as the release of inflammatory 
mediators 184,185(Fig. 16). This hypothesis is supported by the strong association of the disease 
with HLA-II molecules necessary to present antigen to CD4+ T cells and by the presence of 
phagocytic myeloid cells in the lesions. Th1 and Th17 cells are the main effector cells and can 
promote the activation and recruitment of myeloid cells. Both subsets can activate 
macrophages and while Th1 cells lead to the recruitment of monocytes, Th17 cells lead to the 
recruitment of neutrophils. Activated phagocytes, antibodies and complement can cause the 
destruction of myelin and damage to oligodendrocytes and neurons. The antigen(s) 
responsible for MS is still unknown. Furthermore, it is still a debate whether the pathological 
mechanisms of MS develop from a CNS extrinsic or intrinsic event186. According to the extrinsic 
hypothesis, the primary activation of T cells occurs in the periphery due to bystander 
activation, molecular mimicry or other mechanisms (implying bacterial/viral infection or gut 
dysbiosis) and reactivation of the T cells ensues as part of the CNS immunosurveillance, 
leading to the recruitment of more immune cells in the CNS. According to the intrinsic theory, 
a CNS-specific event (such as viral infection or oligodendropathy) leads to damage and 
 28 
 
recruitment of peripheral immune cells (including self-reactive T cells) and inflammation. In 
any case, infiltration of peripheral immune cells results in the formation of MS lesions156 where 
demyelination and subsequent oligodendrocytes and axonal damage can occur. Animal 
models supporting both hypotheses will be discussed in the section III. 
 
Fig. 17 Immune system dysregulation inside the CNS in early and late multiple sclerosis. Calliope A. Dendrou, Lars Fugger 
and Manuel A. Friese, “Immunopathology of multiple sclerosis”, nature reviews immunology 2015;15:545–558183 
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As the disease progresses the chronic inflammation seems to be restricted to the CNS with 
little input from peripheral immune cells71,187 (Fig. 17). In SPMS, immune cells are found in 
organized tertiary lymphoid structures in the meninges containing T cells, B cells, plasma cells 
and dendritic cells. A more diffuse cellular infiltration of the meninges is evident in PPMS. 
Nevertheless, those cells can drive a local chronic inflammation leading to glial dysfunction 
and cortical damage. The inflammatory products promote metabolic and oxidative stress in 
neurons, causing neurodegeneration and brain atrophy188. 
Since the most effective therapy to date for RRMS and the only approved therapy for PPMS 
targets CD20+ B cells189-192 there has been a renewed interest in their role in MS 
pathogenesis70. B cells are a minor part of the inflammatory infiltrate in active RRMS lesions156. 
However, there seems to be increasing evidence for the accumulation of B cells in the 
leptomeninges as the disease progresses183,193,194. B cells can promote disease pathogenesis 
by secreting autoantigen-specific antibodies and proinflammatory cytokines, as well as serving 
as antigen presenting cells and promoting T cell activation.  
c) Current and upcoming treatments 
When deciding which treatment a MS patient should receive, many factors come into 
question. Should the patient get a milder but safer therapy in terms of adverse side-effects, 
or a more potent but risky one? There is still a blatant lack of biomarkers to determine how 
severe or how fast the disease is going to evolve in patients, which makes the decision even 
more difficult. Following the initial approval of IFNβ as a MS drug in the 1990s, many new 
immune modulatory therapies are now available for MS patients, with a diverse range of 
efficacy and tolerability195 (Table 3). Most of these treatments are able to delay (reduce 
relapse rate) but not halt clinical course.  
IFNβ along with glatiramer acetate are typically employed as first line therapy. Second line 
therapies comprise newer drugs that target different aspects of immune functions. The latest 
approved treatment is monoclonal antibodies targeting CD20+ B lymphocytes (Rituximab, 
Ocrelizumab, and Oftatumumab) that is currently the most efficient therapy for the treatment 
of RRMS and also fairly well tolerated196. However, this therapy has modest effects on 
PPMS197. Another drastic therapy that is efficient for treating more aggressive forms of MS but 
is higher in risk is autologous hematopoietic stem cell transplantation (aHSCT)198,199. The 
principal of this therapy is to completely reboot the peripheral immune system using the 
patient’s own bone marrow stem cells.  Patients treated using aHSCT have a higher reduction 
in relapse rate for longer times than with other treatments, even though some patients 
continue to progress.  
The recurrent lack of effect on disease progressions could be due to the confinement of the 
inflammatory response in the CNS. It seems that meningeal inflammation could be sufficient 
to maintain the inflammatory response in the CNS independent of further recruitment of 
immune cells from the periphery. Another possibility is that the chronic inflammatory 
response in the CNS and CSF leads to irreversible and cascading neuronal damage and loss of 
function. 
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Table 3: FDA-approved disease-modifying treatments for MS 
Generic (Administration) Manufacturer (Trade 
Name) 
FDA-Approved 
Indication 
FDA Warnings 
Interferon beta-1a (IFNbeta-1a) 
 
(Injection: Avonex-weekly, Rebif-
thrice weekly. Plegridy – every 2 
weeks) 
 
  
Biogen (Avonex®) May 17, 1996, for CIS 
and RRMS 
Yes 
EMD Serono (Rebif®) August 2014 (Plegridy) Yes 
March 7, 2002, for 
RRMS 
Interferon beta-1b (IFNbeta-1b) 
 
(Injection every other day) 
Bayer Healthcare Pharms 
(Betaseron®) 
July 23, 1993, for RRMS Yes 
Novartis (Extavia®) August 14, 2009, for CIS 
and RRMS 
Yes 
Glatiramer acetate  
(Injection-daily) 
Teva (Copaxone®) December 20, 1996, for 
RRMS 
Yes 
Mitoxantrone (IV) Bedford; Hospira; Teva 
Parenteral; Fresenius; 
EMD Serono Inc., Kabi 
USA, Mylan Institutional; 
Onco Therapies LTD 
2000 for RRMS, SPMS, 
PRMS 
Yes, black box 
Natalizumab (IV) Biogen (Tysabri®) November 23, 2004, for 
RRMS 
Yes, black box 
Teriflunomide Sanofi Aventis US 
(Aubagio) 
(leflunomide by Sanofi 
Aventis US as Arava for 
arthritis) 
September 12, 2012, for 
RRMS 
Yes, black box 
Fingolimod (Oral) Novartis (Gilenya) September 21, 2010, 
RRMS 
Yes 
Dimethyl fumarate (Oral) Biogen (Tecfidera) March 27, 2013, RRMS Yes 
Alemtuzumab (Injection) Genzyme (Lemtrada) November, 2014, RRMS Yes 
CIS = clinically isolated syndrome; FDA = U.S. Food and Drug Administration; IV = intravenous; MS=multiple 
sclerosis; PRMS=primary relapsing multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = 
secondary progressive multiple sclerosis 
 Adapted from Butler M, Forte ML, Schwehr N, et al, “Decisional Dilemmas in Discontinuing Prolonged Disease-Modifying 
Treatment for Multiple Sclerosis”, Comparative Effectiveness Reviews 2015;150200 
III. Experimental autoimmune encephalomyelitis as a model of MS 
 
a) Discovery and development of the model 
The story of how one of the most used animal models for MS was discovered and developed 
is fascinating. Rabies is a fatal disease that is caused by infection with lyssaviruses. The vaccine 
for rabies, developed by Louis Pasteur, was made using weakened virion extracted from dried 
rabbit CNS and it was noticed that some of the vaccinated patients developed encephalitis 
that was not due to viral infection. Thereafter, the first model of experimental encephalitis 
was developed in animals using repetitive injection of CNS extract but it had low incidence 
and, what we would now consider a late disease onset. The discovery that the use of Freund’s 
adjuvant (IFA or CFA) strongly boosted the disease incidence after one or two injections made 
the model more robust in many species201. However, induction of disease in mice was still a 
problem until it was noticed that it required additional injection of pertussis toxin (PTX)202,203. 
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Later, it was found that different CNS proteins could be used to induce disease with different 
clinical courses (monophasic, relapsing remitting, chronic) in different strains and that some 
strains were more susceptible and other more resistant to disease induction184. It is interesting 
to note that there are similarities but also differences in the lesion patterns between MS 
(RRMS and SPMS), human encephalitis due to rabies vaccine, and the EAE models in different 
rat strains (Fig. 18). In all cases primary demyelinating regions with immune cell infiltration 
are evident but while the plaques could affect either brain or spinal cord in MS or post rabies 
vaccination, they are mainly found in the spinal cord in the EAE model. 
 
Fig. 18 Distribution of demyelinating lesions in MS and different EAE-based models. Hans Lassmann and Monika Bradl, 
“Multiple sclerosis: experimental models and reality”, Acta neuropathologica 2017;133(2):223–244184 
EAE: active, passive and spontaneous models 
The work of this thesis is based on the active EAE model in the rat using immunization with 
recombinant myelin oligodendrocyte glycoprotein (MOG) emulsified in PBS/oil (incomplete 
Freund’s adjuvant, IFA). Under this immunization protocol the DA rats are susceptible to 
disease but the PVG rats are resistant. Our group has spent numerous years to identify 
genomic regions affecting susceptibility or resistance to EAE and to determine the candidate 
genes and possible mechanisms involved. DA rats present with a relapsing-remitting disease, 
possibly due to epitope spreading204. Rats are afflicted by an ascending paralysis visually 
assessed using a scoring system of 1-5: score 1 limp tail, score 2 hind limb weakness/affected 
gait, score 3 hind limbs paralysis, score 4 front limb paralysis and score 5 moribund state. 
Lesions most likely start at the lumbar region of the spinal cord and propagate along it, and 
demyelination can also be observed in the hindbrain205.  
We have also used passive EAE that is achieved by transferring myelin-specific T cell lines 
established in vitro using MBP to recipient animals intravenously. This model is mainly used 
to study the effect of T cells in EAE and yields a monophasic disease course with no 
demyelination. Transfer of MBP-specific T cells along with pathogenic autoantibodies specific 
for myelin can induce demyelination. Our lab also acquired a green fluorescent protein (GFP) 
 32 
 
transgenic DA rat strain (DA-GFP) that allowed us to track GFP MBP-T cell lines injected into 
non-GFP recipients or vice versa.  
The mouse model of EAE is now more frequently used than the rat model, mainly due to the 
availability of many different transgenic mouse strains. Several strains of mice were developed 
in which the T cells are all myelin antigen-specific206,207, the most used being the 2D2 mouse 
strain on the C57BL/6 background. These mice develop spontaneous EAE with a low incidence 
(less than 5%), but if these mice are crossed with another strain where B cells are also specific 
for MOG then the incidence of spontaneous EAE increases drastically (50% and more)208. 
There is currently no spontaneous rat model of MS. 
b) Other animal models of MS 
It is important to note that while the EAE model has been very useful in understanding some 
pathogenic mechanisms underlying MS, this model only reflects some but not all aspects of 
the human disease. Furthermore, while we definitely know the antigen in EAE, the trigger(s) 
for MS still remains unknown and the strong artificial induction of the immune response in 
EAE (especially with CFA and/or PTX) biases the immune system in ways that may or may not 
reflect the immune response in MS. There are other models that also recapitulate 
histopathological features of MS, among them being the viral-induced model and a novel 
interesting model of neuroinflammation following primary oligodendropathy. Most of these 
models have been developed in mice. 
Viruses have long been considered potential triggers of MS. While not one specific virus has 
been linked to disease there are several candidates, such as Epstein-Barr virus or 
cytomegalovirus.  The viral-induced animal models support this hypothesis and show that an 
acute pan-encephalitic phase is followed by a second phase in which the immune system 
causes chronic inflammation and demyelination. The two main models are caused by Theiler's 
Murine Encephalomyelitis Virus and the mouse hepatitis virus (MHV) strain JHM, 
respectively209,210. Inflammatory infiltrates consist of lymphocytes and demyelinating 
activated macrophages/microglia. 
The possibility that the autoimmune response observed in MS could be due to a primary 
oligodendropathy has always been a debate. Even though some types of lesions exhibit 
aspects of oligodendrocyte pathology, it is difficult to determine if the death of 
oligodendrocytes is a cause or a consequence of the ongoing inflammation. This is particularly 
true since by the time patients are diagnosed with MS they have most likely already been 
afflicted by the disease for many years. In 2009, Weissman and colleagues reported a study in 
which they attempted to trigger autoimmunity following oligodendrocyte death211. In this 
model, mice expressing the diphtheria toxin receptor on oligodendrocytes were injected with 
the toxin that induces oligodendrocyte death and myelin damage. Despite seeing the 
accumulation of myelin components in the draining lymph nodes they did not observe the 
development of CNS autoimmunity, even when they boosted the immune system by different 
methods such as Treg ablation or activation of APCs with anti-CD40 antibodies. It is important 
to note that following diphtheria toxin injection these mice exhibited a severe phenotype and 
died prematurely. However, in 2015, Popko and colleagues reported induction of immune-
 33 
 
mediated CNS demyelination following oligodendrocyte death212. The model was slightly 
different and used the expression of diphtheria toxin directly in oligodendrocytes, induced by 
tamoxifen which resulted in widespread demyelination. However, the animals survived and 
developed a secondary neuroinflammation and demyelination almost 10 months later with 
increased numbers of CD4+ T cells and myeloid cells in the CNS compared to controls. These 
findings support the ‘inside-out’ hypothesis that a CNS intrinsic event can cause autoimmunity 
in MS. 
c) EAE  pathogenesis 
 
Fig. 19 The role of T helper cell subsets and the cytokine environment in driving autoimmune inflammation. Dietmar 
Herndler-Brandstetter and Richard A Flavell, “Producing GM-CSF: a unique T helper subset?”, Cell Research 
2014;24(12):1379–1380213 
The EAE model relies on the pathogenic action of CD4+ T cells and how they orchestrate a 
subsequent inflammatory response in the CNS leading to demyelination, oligodendrocyte 
death and axonal damage214. My thesis focuses on the recombinant MOG-EAE model in the 
DA rat, but most of the current knowledge of EAE arises on studies of mice. The DA-MOG 
model depends not only on the generation of MOG-specific T cells but also the presence of 
MOG-specific demyelinating antibodies204. The different immunization protocols in EAE boost 
the generation of antigen-specific CD4 T helper cells (Fig. 19). For a long time, Th1 CD4+ cells 
were considered to be the pathogenic T cell subset responsible for disease. Th1 cells are 
generated via the transcription factor Tbet after their activation in the presence of IFNγ and 
IL-12 (signal 3), as mice deficient for the subunit of IL-12, IL-12p40, were resistant to EAE215. 
However mice deficient in the IL-12p35 subunit were not protected and developed 
exacerbated disease215, and this was also true for IFNγ-deficient mice216. It was then 
understood that the IL-12p40 subunit was shared between 2 different cytokines, IL-12 and IL-
23, and that IL-23p19-deficient mice were also resistant to EAE217,218. This led to the hypothesis 
that another subset of T helper cells might be pathogenic, namely Th17 which are generated 
via the transcription factor RORγt in the presence of the cytokines IL-1β, IL-6 and TGFβ. While 
IL-23 is necessary for Th17 cells to become pathogenic by promoting their production of GM-
CSF, IL-1β promotes GM-CSF production219,220. GM-CSF in turn can induce IL-23 production by 
APCs. Unsurprisingly, mice deficient in RORγt, IL-6, IL-1β or GM-CSF are all resistant to EAE221-
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223. However, mice deficient in IL-17a, the hallmark cytokine of Th17 cells, are partially or not 
resistant224,225. These findings seem to pinpoint the importance of GM-CSF production by Th 
cells for EAE pathogenesis and a new subset of T cells called GM-CSF+ Th cells generated with 
IL-2 or IL-7 and dependent on the transcription factor STAT5226,227. While most of the work 
was done on Th17, Th1 cells, even in the absence of RORγt, can produced robust amounts of 
GM-CSF through other unknown regulatory mechanisms.  
All three subsets of T helper cells, Th1, Th17 and GM-CSF+ Th, can induce passive EAE when 
transferred into recipient animals. Furthermore, Th differentiation seems to be highly plastic 
and influenced by the cytokine milieu. In the CNS of EAE affected mice, fate mapping 
experiments have shown that there are many ex-IL17 producing that have switched to IFNγ 
production228 (Fig. 7).  It is very likely that all subsets might have a role at one point in time or 
another in MS pathogenesis as many Th cytokines levels are increased in MS patients (Table 
4). 
Table 4 : Major cytokines contributing to the pathogenesis of MS and EAE 
Cytokine Main Producers 
Levels in 
MS 
Patients 
Role in EAE Potential Treatments of MS 
GM-CSF T cells Elevated GM-CSF-deficient mice are completely resistant to EAE229 
Phase 1b trial of humanized anti-GM-
CSF mAb MOR103 in MS is 
completed230 
IFN-β pDCs Not reported 
Ifnb−/− mice exhibit increased 
EAE severity231 First line treatment of RRMS
232 
IFN-γ Th1 cells, NK cells, NKT cells Elevated 
Ifng−/− mice exhibit increased 
EAE severity216 
Intravenous infusion of IFN-γ 
exacerbates disease in MS patients233 
IL-1β Monocytes, macrophages Elevated 
Il1r1−/− mice are resistant to 
EAE234 Not reported 
IL-10 
Tregs, 
macrophages, 
DCs, B cells 
Reduced Il10
−/− mice exhibit increased 
EAE severity235 Not reported 
IL-12 DCs, macrophages Elevated 
IL-12 p35−/− exhibit increased 
EAE severity236 
Anti-IL-12/IL-23 p40 mAb 
Ustekinumab does not show efficacy 
in treating RRMS in phase II trial237 
IL-17 Th17 cells, γδ T cells, NKT cells Elevated 
Il17a−/− mice are partially 
resistant to EAE225 
Anti-17A mAb Secukinumab reduces 
disease severity in RRMS patients238 
IL-23 DCs, macrophages Elevated 
Il23r−/− mice are completely 
resistant to EAE217 
Anti-IL-12/IL-23 p40 mAb 
Ustekinumab does not show efficacy 
in treating RRMS in phase II trial237 
TNF-α Macrophages Elevated Tnfrsf1a−/− mice are partially resistant to EAE239 
Treatment of MS patients with anti-
TNF-α exacerbates disease in MS 
patients240 
GM-CSF: granulocyte-macrophage colony-stimulating factor; IFN: interferon; IL: interleukin; TNF: tumor necrosis factor; 
DCs: dendritic cells; pDCs: plasmacytoid dendritic cells; NK: natural killer; NKT: nature killer T; Tregs: regulatory T cells; 
RRMS: relapsing-remitting multiple sclerosis; mAb: monoclonal antibody. 
Adapted from Pushpalatha Palle, Kelly L. Monaghan, Sarah M. Milne and Edwin C.K. Wan, “Cytokine Signaling in Multiple 
Sclerosis and Its Therapeutic Applications”. Medical Sciences 2017;5(4):23 
Myeloid cells present in the CNS of EAE animals contribute to demyelination and 
inflammation. However, while CNS parenchymal resident microglia seem to be important for 
debris clearance and healing, monocytes/macrophages seem to promote demyelination241,242. 
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2. Thesis aim 
This thesis addressed mechanisms by which genetic (CLRs) and environmental (vitamin D) 
factors regulate susceptibility to rat EAE induced by immunization with recombinant MOG. 
The aim was to study the regulation of pathogenic T cell development in EAE. Furthermore, 
we assessed the relevance of our findings in the human disease MS, bringing novel insights to 
the pathological mechanisms underlying disease. 
In paper I we provided new light on the functional characteristics of BMDCs frequently used 
in vitro to study the responses of different subsets of myeloid cells. In papers II and III we 
described two distinct mechanisms affecting the differentiation of pathogenic Th17 and 
regulating EAE. 
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3. Results, discussion and future perspectives 
The approaches used during my PhD work are part of the strategies employed in our 
laboratory. The aim of the Neuroimmunology Unit is to study neuroinflammation, particularly 
in the context of MS, exploring different aspects of disease, from genetic and environmental 
influences to molecular and cellular mechanisms driving pathogenesis. Our research also relies 
on a translational approach combining pre-clinical investigation in rodent models of MS and 
clinical data from human studies, towards the ultimate goal of a better care of MS patients.  
In that context, the first paper addresses a basic immunological question: to what extent an 
ex-vivo experimental protocol affects the cellular phenotype of cultured cells, in light with 
their in-vivo counterparts. The “BMDC” project arose from the interest in utilizing bone-
marrow derived DCs for a project I started with when I arrived in the Unit. While the initial 
study did not yield any promising results and was eventually stopped, the experimental setting 
I performed to generate BMDCs further questioned me on the phenotypic heterogeneity of 
cultured cells ex-vivo and their potential application for pre-clinical and clinical investigations. 
In other words, how different are cells in my Petri dish when I use different protocols to 
generate what is often grouped under the umbrella of ‘BMDCs’? What functions can those 
cells fulfill and what would be the closest in vivo counterpart to those in vitro generated cells? 
Our results were in accordance to that reported in mice243 and we could further complement 
the findings with a more functional approach. 
 
Fig. 20 BMDCs generated with GM-CSF/IL-4 or FLT3l are phenotypically different 
Together with my colleague Andreas Warnecke, we demonstrated that, on the one hand, 
FLT3l-generated BMDCs (FL-BMDCs) were functionally closer to DCs in vivo. FL-BMDCs were 2 
subpopulations (CD103+ and CD45R+), the CD103+ cells constitutively expressed CD86, CD40 
as well as high levels of MHC II (Fig. 20). FL-BMDCs secreted IL-6 and IL-12 and were excellent 
at stimulating CD4+ T cells, notably towards the Th17 phenotype. Moreover they expressed 
genes known to be specific for in vivo DCs. Conversely, GM-CSF- and IL-4-generated cells (G4-
BMDCs) expressed higher levels of MHC-I, CD11b, CD11c as well as CD80 (Fig. 20) and could 
upregulate MHC II and CD86 upon stimulation. They were excellent producers of pro-
inflammatory cytokines (e.g. TNF) and reactive nitrogen species (NO), and favored the 
differentiation of CD4+ T cells to Tregs. Our work, along with that of others, supports the idea 
that while FL-BMDCs are phenotypically closer to cDCs, G4-BMDCs are closer to inflammatory 
monocytes derived cells (MCs), often called DCs for their expression of CD11c. 
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Fig. 21 Schematic for the in vivo trafficking experiment using an IVIS machine 
 
An interesting follow-up to this project would be to study the behavior of these cells in vivo. 
We performed preliminary work tracking the migration of subcutaneously injected FL- and G4-
BMDCs using the in vivo imaging system (IVIS) (Fig. 21) and could detect a preferential 
migration of FL-BMDCs to the draining LNs while G4-BMDCs primarily remained at the 
injection site (Fig. 22).  
 
Fig. 22 Tracking of near IR labeled FL- and G4-BMDCs 
We also became interested in testing the capacity of these cells to promote immune responses 
to antigen in vivo and came across major challenges in this effort, mainly due to their very high 
capacity at picking up and presenting antigens from proteins present in the culture media. 
Time did not permit to continue with this part of the project but there is definitely an interest 
in using different types of in vitro generated myeloid cells for different tasks in vivo. Future 
work could, on one hand, explore the potential of FL-BMDCs in vaccination. As those cells are 
excellent at activating T cells and promoting Th1 and Th17 cells they would be suitable 
candidate to initiate an immune response. On the other hand, G4-BMDCs could be 
investigated in the context of cancer immunology and breaking tolerance. Those cells could 
play a role in  promoting inflammation and should have the capacity to cross present antigen 
to cytotoxic CD8+ T cells since they express high level of MHC-I.  
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Our laboratory is interested in neuroinflammation, particularly in the context of MS, and has 
spent numerous years identifying genetic loci regulating MS (as part of global GWAS studies244-
246) and EAE (quantitative trait loci identified in rats247-250). I joined the group at a time when 
the focus changed from identifying the genomic regions involved in EAE regulation to 
narrowing down the gene(s) responsible for the phenotype observed and determining their 
mechanisms of action. This was the aim of my second paper, which is still in a manuscript form 
although near completion and has been my main project in the laboratory. I was fortunate to 
join my colleague Sevasti Flytzani on a project with a very strong phenotype (drastic reduction 
in EAE incidence in the congenic rats) and a rather small genomic region affecting the 
phenotype. The evident phenotype promised optimal conditions to ”easily” decipher the 
underlying mechanisms. My naive optimism was quickly mitigated over the years and I 
appreciated studying how PRRs and DAMPs can contribute to autoimmunity. Our findings so 
far showed how 2 PRRs of the C-type lectin family, MCL and Mincle, could regulate EAE 
incidence by affecting the reactivation of CD4+ T cells in the CNS (Fig. 22). The congenic rats 
(CLRc) had a reduced expression of both receptors compared to DA littermate controls and 
were protected from EAE. MCL and Mincle are both expressed by myeloid cells and we could 
detect them on neutrophils, monocytes and macrophages, but not microglia. We observed a 
defect in T cell activation in the CNS of congenic animals that particularly affected Th17 cells 
(IL-17a and GM-CSF production and proliferation). This resulted in a reduced recruitment of 
granulocytes into the CNS. We pinpointed the potential in vivo ligand of these two receptors 
as SF3B3 (SAP130), an endogenous nuclear protein that can be released by necrotic cells. We 
showed that blocking this protein in vivo in the CNS could protect rats from developing EAE. 
We also started to explore another potential source of SAP130 and speculated that activated 
macrophages could actively release this protein in a similar manner than the release of 
HMGB1 by LPS stimulated macrophages251. So far, we could discern that macrophages 
stimulated with TNF could translocate the protein from the nucleus to the cytoplasm but those 
are still preliminary results. Finally, we could observe hyperactivity in the MCL/Mincle 
signaling pathway in monocytes from MS patients which could be due to the increased 
expression of MCL, Mincle and CARD9 during inflammation in MS patients compared to 
controls. 
Our manuscript is the first to demonstrate mechanisms by which CLRs MCL and Mincle could 
regulate susceptibility to EAE. Indeed, one other previous report has examined the effect of 
those receptors in EAE in mice96, but they did not address the mechanisms. Additionally, the 
authors used the MCL/Mincle ligand TDM as adjuvant in replacement of heat-killed 
mycobacteria for EAE induction. It is therefore impossible to determine if under those 
conditions the role of these receptors was important in either the peripheral and/or CNS 
activation of T cells. Others groups have shown an important role of Mincle in 
neuroinflammation, such as in experimental autoimmune uveoretinitis (EAU)252, 
stroke104,107,253,254 and traumatic brain injury (TBI)106. Interestingly, in EAU the absence of 
CARD9 and Mincle were linked to a defect in Th17 response252, whereas in TBI the 
inflammatory response was associated to Mincle and SAP130106. We have shown that the 
expression of MCL and Mincle in the rat CNS, most likely in myeloid cells of the meninges, was 
crucial for the reactivation of CD4+ T cells to the Th17 phenotype, and that this effect was 
 39 
 
partially due to SAP130. Following the hypothesis that MS could be due to a hyperactive 
immune system, we could observe an increased response to the MCL/Mince ligand TDB in MS 
monocytes compared to in healthy controls. We did not observe this difference following 
stimulation with the TLR4 agonist LPS. This pinpoints the specific dysregulated response of the 
MCL/Mincle signaling pathway, which could contribute to the overall inflammatory response 
in MS.  
 
Fig. 23 Possible mechanism of action in the meninges of DA rats which is defective in CLRc congenics due to low expression 
of MCL and Mincle. 
We are still investigating the mechanism of action of SAP130 in vivo, particularly since we 
failed to stimulate macrophages in vitro with the commercially available recombinant SAP130 
proteins. This could be due to the fact that most of those are partial recombinant proteins and 
this could affect their capacity to bind to MCL and Mincle. We are attempting to determine if 
macrophages can release and respond to endogenous SAP130. Moreover, further work is still 
needed to address the relevance of this rat study for MS pathogenesis and its potential 
treatment application. It would be very interesting to determine how much of this mechanism 
observed in rats translates into humans. The study by de Riverro Vaccari et al pointed to a role 
of at least Mincle in neuronal response to SAP130 during TBI suggesting that it could induce 
neuronal death106. One could speculate the occurrence of similar mechanisms in the brain of 
MS patient as well. To address this question, one could determine MCL and Mincle expression 
by neurons and test for the accumulation of SAP130 protein in situ by immunohistochemistry 
in post-mortem brain sections from MS patients compared to non-neurological controls. The 
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aforementioned diversity of MS lesions further requires careful selection of clinical material. 
This, together with detection of SAP130 in CSF of MS patients could provide insights into the 
relevance of SAP130 and MCL/Mincle-related pathways in MS. Importantly, considering the 
extensive clinical heterogeneity of patients affected with MS, e.g. in disease course, symptoms 
and severity, one could hypothesize that SAP130/MCL/Mincle-related processes would play a 
role in a subset of MS patients, affecting neuroinflammatory and possibly neurodegenerative 
processes. Moreover, more effort is needed in order to decipher the mechanism underlying 
the observed hyperactive MCL/MINCLE response in MS patients, for example with regards to 
genetic variation predisposing to such response. Indeed, while considerable effort has been 
made in identifying genetic risk variants predisposing for disease, much less is known about 
the genetic factor predisposing for specific cellular response in a context-specific manner. 
Ultimately, the question whether MCL/MINCLE signaling pathway could be a target for 
therapy would need to be addressed, our data seems to be pointing at a role of this pathway 
at the initiation phase of the disease which is not possible to treat in MS as most patients are 
diagnosed with the disease years after onset. However MCL/MINCLE signaling could still play 
a role during relapse and therefore be targeted with blocking antibodies for example.  
Other than genetics, our laboratory also has a particular interest in environmental factors that 
affect MS and EAE. Paper III is a follow-up of a previous study255 that showed the importance 
of vitamin D in adolescent rats for EAE protection. Interestingly, while the beneficial role of 
vitamin D in MS is well established, the mechanisms underpinning protection, and more 
specifically immunomodulation, exerted by vitamin D, are poorly known. 
 
Fig. 24 Schematic illustration of study design from paper III256 
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Herein, using omics approaches in rodents, we described the epigenetic mechanisms of action 
of vitamin D on CD4+ T cells that affect proliferation and Th17 differentiation. Even though my 
main supervisor is an expert in epigenetics I personally didn’t work directly on epigenetic 
mechanisms regulating inflammation. My main contribution to this project was from an 
immunological perspective. When I joined the lab my first project was to establish the passive 
EAE model with MBP-specific T cells and we used this method to address the effect of vitamin 
D on T cell activation. The whole paper showed how vitamin D affects CD4+ T cell activation 
in vivo via changes in DNA methylation and miRNA expression, which in turns affected the 
expression of many genes involved in cytokine and T cell receptor signaling as well as cytokine 
production (notably IL-2). This led to impaired Th differentiation by the T cells, notably the 
Th17 phenotype, as well as defect in cell proliferation. We used the adoptive transfer model 
to prove that even short-term treatment with vitamin D impacted effector T cell activation 
into Th1, but even more so for Th17 cells and drastically reduced their proliferation. These 
cells were less encephalitogenic when transferred to the recipient rats compared to untreated 
cells. This study not only provides a mechanism underlying the effect of vitamin D treatment 
of juvenile rats on CD4+ T cells and susceptibility to EAE, but also provides functional evidence 
that vitamin D affects the pathogenic potential of CD4+ T cells directly.  
 
Fig. 25 Schematic representation of Jak/Stat, Erk/Mapk, Pi3k/Akt, Vegf, TCR, and IL-3 signaling that are affected by vitamin 
D. Orange indicates genes that are differentially expressed and methylated. Blue indicates genes that are differentially 
expressed only, and yellow indicates genes that are differentially methylated only.256 
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Future work could study the mechanism of vitamin D effect on APCs in a similar manner, as 
they also express VDR. Also, it would be interesting to distinguish the contribution of vitamin 
D on the direct response by T cells or the modulation of T cell response via APCs. Our findings, 
together with other studies, further encourage the use of vitamin D supplementation, 
probably in case of deficiency during critical timeframe of risk to autoimmunity. In addition to 
prophylactic perspective, the potential of vitamin D supplementation as a therapeutic tool in 
patients with established MS disease is still controversial257. Examining the effect of vitamin D 
treatment on PBMC activation in vitro in response to antigen (myelin or others), could shed 
some light on its mechanism of action in humans. In light with our findings, one could 
speculate about a putative beneficial effect of vitamin D treatment in combination with other 
conventional immunomodulatory agents.   
Overall, using different approaches in rodent models and human material, the work presented 
here provides additional insight into the immunological aspects of MS-like disease and further 
highlight the importance of utilizing adequate experimental settings and complementary and 
integrative strategies to tackle a biological question. Our results support the “hyperactive 
immune system” theory, showing how PRRs and environmental factors such as vitamin D 
levels can affect the immune system to promote pathogenic inflammation. There are many 
more identified risk factors for MS but we are still not nearer to finding a cure, even though 
the disease modifying therapies have evolved very fast this past decades and are getting more 
and more efficient at reducing relapse rate and slowing down the disease. More efforts needs 
to be put on several aspect of MS. There is still many other genes that can contribute to 
disease and their underlying mechanisms remain unknown. Identifying more functional 
pathways involved in MS pathogenesis will help to determine how to best treat patients with 
more targeted therapies. Currently we lack the possibility of knowing whether a patient 
diagnosed with MS will have a slow disease progression or a more aggressive one. We need 
better biomarkers to stratify patients into potential mechanistic subgroups that will enable 
more personalized therapy. Finally, we need a better understanding of CNS intrinsic events 
that could provide a clue to the disease etiology but also mechanisms of progression. The main 
limitation of the EAE model is that it is made to boost a CD4+ T cell mediated disease, studying 
other models such as the viral models or models based on primary neuropathy will help better 
understand the “more sensitive CNS” theory of MS pathogenesis. It doesn’t mean that the EAE 
model is obsolete but research would benefit from using different models reflecting different 
aspects of MS. In that context, a bi-directional approach of research combining studies in both 
human and animal material appears critical. Indeed, determining the relevance of 
mechanisms identified in animal models using clinical material and, addressing the pathogenic 
mechanisms of risk factors observed in human using in vivo/in vitro laboratory experiments 
will help understand the disease pathogenesis. Moreover, identifying risk factors affecting 
disease progression and their underlying mechanism will provide more light on what makes 
the CNS tip towards degeneration. Furthermore, mechanisms promoting repair in the CNS are 
crucial and would provide a useful complementary therapy to the current immunomodulatory 
drugs by promoting recovery. It is no trivial matter to dissect the pathogenesis of complex 
diseases such as MS but the international effort in understanding the disease and the 
aspiration to provide patients with better care is moving in the right direction. The future for 
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MS patients probably relies on ”precision medicine” with precise phenotyping of the patients 
first (in terms of their unique load of risks and dysfunction, and in terms of prediction of 
disease course and severity/treatment response) and targeted therapy attuned to their 
disease sub-phenotype. 
Personal reflections: 
During my years in the Neuroimmunology Unit I had to adapt to working with rats as I was 
working with mice during my masters. First, rats are way bigger than mice, which can seem 
very impressive at first, and second there is much less knowledge and reagents available to 
study immunology in rats than for mice or human cells. The first impression was easily 
changed since rats are very smart and relaxed animals, and handling them is far easier than 
handling mice. The second challenge was in the end very stimulating and I enjoyed establishing 
protocols for the passive EAE and bone marrow chimera techniques. This challenge also forced 
me to address not only complex questions with less conventional approaches but also to 
determine if some basic knowledge from mice held true for rats. Because this is an integrative 
multidisciplinary unit I had the opportunity to deepen my knowledge not only in immunology 
but in human and rodent genetic, epigenetic, stem cell therapy as well as to discover other 
models of neuroinflammation such as traumatic brain injury. It was a great opportunity to 
grow as an independent researcher in this group. 
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Unit. Finding a PhD position was very difficult for me because of complicated relations with 
my previous supervisor and I was very close to giving up pursuing a career in research when 
you suddenly answered positively to my email. It was such a shock I had to ask my sister to 
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on the project but enough freedom to really learn how to become an independent scientist. 
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or harsh word to put me back on track and I am forever grateful for it. We laughed and cried 
together, discussed science, project, plans and dreams. I have no ideas how many times I came 
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many years together with you! I am not going to say that it was perfect every day, like a family 
we bicker but in the end we stick together and help each other out. And we are always happy 
for each other’s success! A special thanks to Lara and Eliane who were my lifeline in this PhD 
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even though you probably didn’t understand anything, for simply being there and giving 
advice and the good laugh! Taylan I hope you will become a scientist one day like tatie. And 
Nabiha, who is far away but so close to my heart, you pushed me to believe in myself and that 
I can make it no matter what, I am so proud of your career in journalism. 
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